Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
Meenakshi Anurag(Baylor College of Medicine), Matthew J. Ellis(Washington University in St. Louis)
Cited by 133
Related Papers
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial
|Journal of Clinical Oncology|2001|1.1k
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2010|823
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
|The Lancet|2016|599